NCT01189643进行中（未招募）1 期
A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- To define the tolerability
研究概览
简要总结
This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 29 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 1 year, less than 30 years
- •Newly diagnosed, previously untreated patients with histologically or molecularly confirmed DSRCT
- •Adequate hematologic function:
- •Absolute neutrophil count ≥ 1,000/mm3
- •Platelet count ≥ 100,000/mytm3
- •Adequate renal function:
- •Normal creatinine for age OR
- •Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2
- •Adequate hepatic function:
- •Total bilirubin ≤ 1.5 x the ULN for age
- •AST ≤ 2.5 x the ULN for age [in the absence of hepatic involvement of tumor]
- •Normal cardiac function
- •Shortening fraction greater than or equal to 28% by echocardiogram OR
- •Left ventricular ejection fraction (LVEF) greater than or equal to 50% on technetium-99m pertechnetate radionuclide cineangiography (MUGA) or echocardiogram
- •Hypertension must be well controlled on stable doses of medication for at least two weeks prior to enrollment.
- •Patients must consent to an indwelling central venous catheter.
- •Sexually active patients of reproductive potential must be willing to use an effective method of contraception.
排除标准
- •Prior chemotherapy or radiotherapy
- •Pregnant or breastfeeding females
- •Patients with documented chronic non-healing wound, ulcer or bone fracture.
- •Incomplete healing from previous oncologic or other major surgery.
- •Surgical procedures:
- •Patients who have undergone major surgery (including open biopsy, thoracotomy, organ resection, exploratory laparotomy, arteriovenous grafts) <28 days prior to enrollment will have bevacizumab dosing delayed as outlined in section 9.1
- •Patients must be at least 48 hours from placement of central catheter before receiving first dose of bevacizumab
- •Minor surgical procedures (needle/laparoscopic core biopsies) for limited purposes of tissue retrieval will be allowed. Patients should not receive the first planned dose of bevacizumab until the wound is healed and 7 days have elapsed since the procedure.
- •Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation).
- •Thrombosis:
- •Patients must not have had a deep venous or arterial thrombosis (non-central venous catheter related) within the last three months prior to study entry.
- •Patients with cerebrovascular accident or transient ischemic attack within 6 months of therapy are excluded
- •History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study entry.
- •CNS status: Patients must not have known CNS metastases or leptomeningeal disease.
- •Screening with brain imaging is not required for asymptomatic patients. Proteinuria: Urine protein: creatinine ratio greater than or equal to 1.0
- •Uncontrolled hypertension (defined as SBP and/or DBP > 95th percentile for age)
- •Prior history of hypertensive crisis or hypertensive encephalopathy
- •NYHA Grade II or greater congestive heart failure
- •History of myocardial infarction or unstable angina within 12 months prior to Day 1
- •History of stroke or transient ischemic attack
- •Significant vascular (e.g., aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1
- •History of hemoptysis (greater than or equal to 1/2 teaspoon of bright red blood per episode) within 1 month prior to Day 1
- •Known hypersensitivity to any component of bevacizumab
研究组 & 干预措施
Chemotherapy
Experimental
This is a pilot study to evaluate the acute toxicities and activity of irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator based therapy in newly diagnosed patients with DSRCT.
干预措施: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator (Drug)
结局指标
主要结局
To define the tolerability
时间窗: 2 years
of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT
To define adverse event profile
时间窗: 2 years
of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT
次要结局
- To estimate the response rate of two cycles of irinotecan, temozolomide and bevacizumab(2 years)
- To estimate time to progression(2 years)
- To assess use of 18FDG PET-CT(2 years)
- To estimate survival(2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) TumorsCentral Nervous System TumorsNCT00876993Johns Hopkins All Children's Hospital26
终止
3 期
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line TherapyRecurrent Colon CancerRecurrent Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal CancerNCT00499369National Cancer Institute (NCI)72
已完成
2 期
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal CancerColorectal CancerNCT00483834University Health Network, Toronto50
已完成
2 期
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung CancerCarcinoma, Small Cell LungNCT00294931SCRI Development Innovations, LLC50
已完成
1 期
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid TumorsBrain and Central Nervous System TumorsUnspecified Childhood Solid Tumor, Protocol SpecificNCT00138216Children's Oncology Group42